Updating results

737 results

Sort: Relevance | Date

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Technology appraisal guidance In development

Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

In development [GID-TA10248] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Technology appraisal guidance In development

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Technology appraisal guidance In development

Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Technology appraisal guidance In development

Ivosidenib for treating relapsed or refractory acute myeloid leukaemia ID1548

In development [GID-TA10416] Expected publication date: 28 April 2021

Technology appraisal guidance In development

Intrapartum care: existing medical conditions or obstetric complications

In development [GID-QS10081] Expected publication date: 28 February 2020

Quality standard In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: 21 April 2021

Technology appraisal guidance In development

Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Technology appraisal guidance In development

Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Technology appraisal guidance In development

Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Technology appraisal guidance In development

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

In development [GID-TAG496] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Technology appraisal guidance In development

Electrohydraulic lithotripsy for difficult-to-treat bile duct stones

In development [GID-IPG10151] Expected publication date: TBC

Interventional procedures guidance In development

Transapical transcatheter mitral valve-in-valve implantation for a failed surgically-implanted mitral valve bioprosthesis

In development [GID-IPG10152] Expected publication date: TBC

Interventional procedures guidance In development

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 19 May 2021

Technology appraisal guidance In development

Galcanezumab for preventing cluster headache [ID1212]

In development [GID-TA10425] Expected publication date: 24 February 2021

Technology appraisal guidance In development

Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Midostaurin for treating advanced systemic mastocytosis ID1573

In development [GID-TA10503] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 21 December 2020

Medical technologies guidance In development

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Deep brain stimulation for refractory epilepsy

In development [GID-IPG10129] Expected publication date: 20 May 2020

Interventional procedures guidance In development

Transcranial magnetic stimulation for obsessive-compulsive disorder

In development [GID-IPG10134] Expected publication date: 20 May 2020

Interventional procedures guidance In development

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

In development [GID-TA10389] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma [ID2708]

In development [GID-TA10588] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Behaviour change: digital and mobile health interventions

In development [GID-NG10101] Expected publication date: 05 August 2020

NICE guideline In development

Management of gout

In development [GID-NG10151] Expected publication date: 04 April 2022

NICE guideline In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

Selective internal radiation therapy for unresectable colorectal metastases in the liver

In development [GID-IPG10124] Expected publication date: 04 March 2020

Interventional procedures guidance In development

MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy

In development [GID-IPG10122] Expected publication date: 04 March 2020

Interventional procedures guidance In development

Cyanoacrylate glue occlusion for varicose veins

In development [GID-IPG10128] Expected publication date: 04 March 2020

Interventional procedures guidance In development

Bilateral cervicosacropexy or vaginosacropexy using mesh for pelvic organ prolapse

In development [GID-IPG10123] Expected publication date: 04 March 2020

Interventional procedures guidance In development

Artificial iris insertion for acquired aniridia

In development [GID-IPG10130] Expected publication date: 22 April 2020

Interventional procedures guidance In development

Artificial iris insertion for congenital aniridia

In development [GID-IPG10144] Expected publication date: 22 April 2020

Interventional procedures guidance In development

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

In development [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

In development [GID-TA10589] Expected publication date: TBC

Technology appraisal guidance In development

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

In development [GID-TA10573] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Technology appraisal guidance In development